AndroMETa-Lung-536: Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC
Condition: Non-Small Cell Lung Cancer
Sponsor: AbbVie
Full Title
Protocol M24-536: An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal Dose of
Telisotuzumab Adizutecan in Combination with Budigalimab in Advanced or Metastatic Non-Squamous NSCLC with No
Prior Treatment for Advanced Disease and No Actionable Genomic Alterations
Study Treatment
c-MET targeting antibody-drug conjugate telisotuzumab adizutecan in combination with investigational anti-PD-1 antibody budigalimab or standard chemo/immunotherapy.
Eligibility/Info
Part 1:
1L Cohort: No prior systemic therapy in the advanced/metastatic setting
2L Cohort: Participants without an actionable genetic alteration must have progressed on (or be considered ineligible for) platinum-based chemotherapy or immune checkpoint inhibitor (as monotherapy or in combination with chemotherapy). Participants with an actionable genetic alteration (other than EGFR) must have progressed on (or be considered ineligible for) anti-cancer therapy targeting driver gene alteration or platinum-based chemotherapy.
Part 2:
Participants must have had no prior systemic therapy for locally advanced or metastatic NSCLC.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
